degree of myocardial damage in patients with ACS has rarely been investigated. 10 Moreover, little is known about the correlation between increased platelet reactivity and 30-day clinical outcomes in patients with ST-segment elevated (ST-se) AMI who are undergoing primary PCI.
Measurement of CD62p expression using flow cytometry has been shown to be a sensitive, specific, and useful tool in daily clinical practice for assessing platelet activation, because it quickly analyzes a large number of cells to identify the proportion and extent of platelet activation. 5, 11 Thus, this study investigated whether platelet activity is substantially enhanced in patients with ST-se AMI, and whether increased platelet activity is predictive of the extent of myocardial damage and 30-day composite major adverse clinical outcomes (MACO).
Methods

Patient Population and Inclusion Criteria
In our hospital, all patients with AMI are considered eligible for primary PCI. For the purposes of this study, platelet activation (expressed by CD62p) of patients admitted during daylight hours who underwent primary PCI were prospectively measured by flow cytometry (B & D). To circumvent other potential influences on the platelet activity, we excluded patients with a history of recent surgery or trauma during the preceding 2 months, renal insufficiency (creatinine >1.5 mg/dl), bleeding tendency, malignancy or liver cirrhosis, febrile disorders, acute or chronic inflammatory disease at study enrollment, or myocardial infarction (MI) onset <3 months. Thus, between May 2004 and February 2005, 45 consecutive patients of any age who presented with AMI of <12 h duration and underwent primary PCI were prospectively investigated and recruited.
Twenty subjects matched for age, gender, hypertension, diabetes mellitus, current smoking and hypercholesterolemia were assigned to the at-risk control group and 20 ageand gender-matched healthy volunteers were assigned to the healthy control group. Informed consent was given by each study subject. The hospital's Institutional Review Committee on Human Research approved the study protocol.
Procedure and Protocol
A transradial artery approach using a 6-French arterial sheath is routinely used for treatment of AMI unless both hands of an Allen test are positive. A 6-French Kimny Miniradi (Boston Scientific, Scimed, Inc Maple Grove, MN, USA) was used for diagnosis and primary PCI.
Left ventriculograms, which were immediately performed after angioplasty, were recorded in the 30°right anterior oblique and 60°left anterior oblique views.
From May 2002, the PercuSurge GuardWire™ device (Medtronic AVE) was used for consecutive patients presenting at hospital with AMI (<12 h duration). Enrollment and exclusion criteria and the procedure have been previously described in detail. 12 Clopidogrel (300 mg loading dose before stenting then 75 mg/day) was given for at least 4 weeks to patients who underwent primary stenting. Aspirin (100 mg orally once a day) was given indefinitely to each patient. Other drugs commonly prescribed were angiotensin-converting enzyme inhibitors (ACEIs), -blockers, isonitrate and diuretic drugs.
Blood Sampling and Assessment of Platelet Activity
Blood samples were obtained once from healthy volunteers during healthy clinic examination and from at riskcontrol subjects in the outpatient department. Blood samples from AMI patients were drawn prior to any medical treatment. Venous blood was obtained from the antecubital vein. Biochemical measurements employed standard laboratory methods.
Blood (4 ml) was drawn into a vacutainer containing 3.8% buffered sodium citrate and the mixture of blood and sodium citrate was immediately centrifuged (model 5400; Kubota Corp, Tokyo, Japan) for 15 min at 1,500 rpm at room temperature. Platelet activity was assessed using supernatant platelet-rich plasma.
Platelet activity was determined with respect to -granule degranulation (surface expression of P-selectin or the CD62p antigen). Procedural details have been previously described. 5, 11 Briefly, a fluorescein isothiocyanate-conjugated antibody to GP IIIa (CD61; Becton Dickinson) was used as an activation-independent marker of platelets. A phycoerythrin (PE)-conjugated anti-CD62 antibody (Becton Dickinson) was used to assess -granule degranulation. The association of ligands with platelets was determined with a fluorescence-activated cell sorter (FACSCalibur™ system; Becton Dickinson). The control ligand (IgG-PE conjugate) was used to detect any nonspecific associations and to permit the establishment of a threshold for activationdependent binding. The percentage of platelets expressing P-selectin was defined as the fraction exhibiting specific binding (ie, CD62p positive) minus that exhibiting nonspecific binding (ie, percentage defined with the IgG-PE conjugate) of the 10,000 platelets sorted.
Definitions and Data Collection
AMI was defined as the presence of typical chest pain for more than 30 min with ST-segment elevation >1 mm in 2 consecutive precordial or inferior leads. Unsuccessful reperfusion was defined as failure of the infarct-related artery to achieve normal blood flow after PCI (≤Thrombolysis In Myocardial Infarction (TIMI)-2 flow). Reperfusion time was defined as the time from chest pain onset to the first balloon inflation. Detailed in-hospital and follow-up data, including age, sex, coronary risk factors, serial creatine kinase-MB (CK-MB) levels, white blood cell counts, platelet counts, creatinine level, body temperature, Killip score on admission, severity of congestive heart failure (CHF), angiographic findings and number of diseased vessels were collected prospectively and entered into a computerized database.
Endpoints and Statistical Analysis
The study endpoint was the 30-day composite MACO, including advanced CHF (defined as New York Heart Association functional class ≥III) or 30-day death.
Data are expressed as mean ± SD. Categorical variables were compared using chi-square or Fischer's exact test. Continuous variables between 2 groups were compared using the Wilcoxon rank-sum test. Continuous variables among 3 groups were compared using the one-way ANOVA for parametric data and Kruskal-Wallis test for nonparametric data, followed by the post-hoc multiple comparison procedure with the Wilcoxon rank-sum test and Bonferroni correction. Discriminant analysis 13 was used to find the cut-off value of CD62p expression that was the most significant value with good sensitivity and specificity for predicting 30-day MACO. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A value of p<0.05 was considered statistically significant. Table 1 summarizes the baseline characteristics of all the subjects, none of whom received antiplatelet agents prior to blood sampling. There were no significant differences among the 3 groups for age, gender, creatinine levels, or platelet counts, or between AMI patients and at-risk control subjects for coronary artery disease risk factors. Although none of the subjects had fever, the mean body temperature was significantly higher in at-risk control subjects than in either AMI patients or healthy control subjects. Additionally, the white blood cell counts were significantly higher in AMI patients than either of the control groups.
Results
Baseline Characteristics of AMI Patients, At-Risk Control Subjects and Healthy Control Subjects
The intra-assay variability based on repeated measurements of the same blood sample was low with mean coefficients of variance <7.0% in our laboratory. The CD62p expression was substantially higher in AMI patients than in the control subjects.
Baseline Characteristics, Laboratory Findings, Angiographic Results, and 30-Day Clinical Outcomes for AMI patients (Table 2)
CD62p expression ≥8% was the most powerful cut-off value identified by the discriminating test for predicting 30-day MACO, with a sensitivity of 86.7% and a specificity of 97.1%. Thus, patients with CD62p expression of ≥8% were classified into the high platelet activity group (Group 1) and those with CD62p expression <8% were assigned to the low platelet activity group (Group 2). The 2 groups were similar in age, gender, cardiovascular risk factors, previous MI, previous stroke, body temperature, anterior wall MI, and mean reperfusion time. There were no significant differences between them for white blood cell counts, platelet counts, and serum creatinine levels. Angiographic results demonstrated that there was no significant difference in the incidences of multivessel disease, successful reperfusion, and frequency of using a PercuSurge device or stenting between the 2 groups. However, the incidences of cardiogenic shock and advanced CHF were significantly higher in Correlation analysis demonstrated that there was a significant direct relationship between CD62p expression and peak CK-MB level (Fig 1) . Table 3 presents the results of univariate analysis for factors associated with composite 30-day MACO. The most significant factor among these variables was high CD62p expression (≥8%). An LVEF ≤50% was significantly related to an increased incidence of 30-day MACO. There was also a strong correlation between high peak of CK-MB and 30-day MACO, whereas successful reperfusion was associated with decreased 30-day MACO.
Determinants of Composite 30-Day MACO
Multiple stepwise logistic regression analysis of all univariate significant factors in Table 3 showed that only high CD62p expression (≥8%) was significantly and independently associated with composite 30-day MACO (odds ratio =90.99, 95% confidence interval: 11.51-719.21, p< 0.0001).
Discussion
Principal Findings
This study of whether platelet activation expressed by CD62p was enhanced and predictive of the extent of myocardial damage and 30-day MACO in patients with ST-se AMI undergoing primary PCI has 3 major novel findings. First, CD62p expression was significantly higher in AMI patients compared with at-risk control and healthy subjects. Second, CD62p expression was predictive of the severity of myocardial damage as measured by plasma levels of CK-MB. Third, high CD62p expression (≥8%) was independently associated with 30-day MACO.
Platelet Activity is an Index of a Thromboembolic Event
Platelet activity is increased in the clinical setting of ACS, 11, 14, 15 following acute ischemic stroke, 5 and in patients with obstructive coronary artery disease undergoing PCI. 8 The association between elevated platelet activity and unfavorable clinical outcome has been identified in various clinical settings 5, 8, 9 and thus, administration of antiplatelet agents is essential for patients with ACS 3,4,6,7 and after ischemic stroke. 5 A recent study demonstrated that platelet function was more enhanced in ST-se MI than in non-Q MI patients, 10 and a principal finding in the present study was that CD62p expression was significantly higher in AMI patients than in the control subjects, which confirmed the most recent study 10 and further extended the findings obtained in previous studies 5, 8, 15 that platelet activation is an index of a thromboembolic event. Combining our findings with those of the other studies 5, 8, 10, 15 supports the suggestion that early administration of antiplatelet agents and IIb/IIIa receptor inhibitors could provide additional benefit to patients with ACS. 3, 6, 7, 16 Correlation Between Platelet Activity and Myocardial Damage Notably, while the relationship between the thromboembolic risk and platelet activity has been extensively debated, 1, 2, [5] [6] [7] [8] [9] 14 the association between myocardial damage and platelet activation has seldom been studied. 10 Plaque rupture, an index of acute inflammatory stimulus, increases platelet activation 11 and additionally, acute ischemic stroke or AMI, which indicates tissue necrosis, markedly enhances platelet activity. 5, 9 Thus, platelet activity is a sensitive marker of the acute inflammatory process. Importantly, CD62p expression was found to be strongly correlated to the CK-MB peak level in this study. Moreover, CD62p expression was significantly higher in patients with low LVEF than in patients with high LVEF. These findings, which indicate that platelet activation can reflect the severity of myocardial necrosis resulting from acute coronary artery occlusion, further support the findings of previous studies. 5, 9, 11 Frossard et al also demonstrated that platelet function was strongly associated with MI severity, 10 which is supported by our findings, and together these studies raise the possibility that platelet activity is an index of myocardial necrosis.
Association between Elevated Platelet Activation and Unfavorable Clinical Outcomes
A correlation between unfavorable clinical outcome 9 and platelet activation has also seldom been investigated. Another principal finding of the present study was that patients with high (≥8%) CD62p expression had a significantly higher incidence of cardiogenic shock and advanced CHF and lower LVEF than patients with low (<8%) CD62p expression. Additionally, the most important finding in this study was that high CD62p expression (≥ 8%) was independently associated with composite 30-day MACO. Moreover, the striking impact of CD62p expression on the 30-day MACO could not be ameliorated by primary PCI. Therefore, these findings suggest that increased CD62p expression reflects a serious clinical condition in patients following AMI, and encourages the use of platelet activation as an important biomarker for risk stratification in patients after AMI. These suggestions, based on laboratory data and clinical observations, which are corroborated by those obtained by Trip et al, 9 provide a rationale for investigating platelet activation in patients following AMI.
We recently demonstrated that the PercuSurge device can prevent distal embolization and increases the integrity of the microvasculature during primary PCI. 12 In the present study, we found that more than 40% of our patients had received combined therapy of primary PCI and the PercuSurge device. Hence, we posit that this mechanical device suppresses the effect of platelets on unsuccessful reperfusion of epicardial vessel and microvasculature, which has been shown to be strongly associated with unfavorable clinical outcomes in patients with AMI following primary PCI. 12, 15 
Study Limitations
First, the sample size of this study was relatively small. Additionally, near 90% of patients achieved final TIMI-3 flow in the infarct-related artery. Therefore, the relationship between platelet activation and no-reflow phenomenon could not be identified in this study. However, early administration of IIa/IIIb receptor inhibitors can increase final TIMI-3 flow during primary stenting in patients with AMI. 16 Thus, the role of platelet activation is essential for determining successful reperfusion therapy in this clinical setting. Second, based on feasibility, other measurements such as that required to assess platelet function by ADP stimulation, were not taken in our patients; such a measurement would allow direct comparison of the sensitivity and specificity of the methods. This limitation should therefore, be addressed in future studies. Third, statins and ACEIs have recently been suggested to have both anti-inflammatory and antiplatelet properties. 17, 11 In this study, although more than 60% of our patients were treated with statins and ACEIs, these drugs were administered only after the primary PCI and thus, their effect on the suppression of initial CD62p expression can be completely ruled out.
Conclusion
CD62p expression was substantially enhanced in patients with ST-se AMI undergoing primary PCI. Higher levels of CD62p can be used as an independent predictor of the extent of myocardial damage and 30-day MACO.
